Why Humacyte, Inc.’s (HUMA) Stock Is Up 7.85%
As of Friday, August 21, Humacyte, Inc.’s HUMA share price has surged by 7.85%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Commentary & Analysis
Why Humacyte, Inc.’s (HUMA) Stock Is Up 11.59%
As of Wednesday, August 19, Humacyte, Inc.’s HUMA share price has surged by 11.59%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Humacyte, Inc.’s (HUMA) Stock Is Up 22.00%
As of Wednesday, August 19, Humacyte, Inc.’s HUMA share price has surged by 22.00%, which has investors questioning if this is right time to sell.Omar Beirat
Why Humacyte, Inc.’s (HUMA) Stock Is Down 6.51%
As of Monday, August 17, Humacyte, Inc.’s HUMA share price has dipped by 6.51%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Humacyte, Inc.’s (HUMA) Stock Is Up 7.09%
As of Friday, August 14, Humacyte, Inc.’s HUMA share price has surged by 7.09%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | HUMA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $188.7 | $286.3 | 26% |
|
| Shares Out (Mil) | 234.2 | 54.2 | 79% |
|
| Institutional Ownership | 87.6% | 92.8% | 55% |
|
| Float (Mil) | 246.4 | 39.7 | 77% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 13,702 | 534 | 97% |
|
| Price Change (52-week) |
(57.4%) | 58.7% | 12% |
|
| Growth | HUMA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 5.9% | 13.6% | 40% |
|
| Net Income (5yr) | 9.3% | (10.1%) | 54% |
|
| EPS (5yr) | 53.2% | 16.0% | 94 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 50.4% | (15.6%) | 93% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.083) | ($0.400) | ($0.248) | |
| Month Ago EPS | ($0.083) | ($0.350) | ($0.240) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.090) | ($0.393) | ($0.160) | |
| Year/Year Chg | (48.1%) | 55.0% | (57.4%) | |
| Financials | HUMA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $37 | 3% |
|
| Net Income (TTM) (Mil) | ($97) | ($43) | 11% |
|
| EPS (TTM) | ($0.497) | ($1.400) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($97) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($8) | $2 | 31% |
|
| Long-Term Debt (Q1) (Mil) | $65 | $4 | 41% |
|
| Enterprise Value (Q1) (Mil) | na | $160 | na |
|
| Valuation | HUMA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.18 | 2.77 | 82% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | HUMA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (69.9%) | (47.3%) | 8% |
|
| ROE | (547.9%) | (55.0%) | 1% |
|
| Liabilities to Assets | 77.4% | 29.6% | 73% |
|
| F-Score | 2 | 2 | 7% |
|
Humacyte, Inc. did not pass any screens on 8/20/2026.
